UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000039188
Receipt No. R000044692
Scientific Title Comprehensive analysis of blood tryptophan metabolites and fatty acids in patients with lung cancer treated with immune checkpoint inhibitors
Date of disclosure of the study information 2020/01/20
Last modified on 2022/07/20 (Ver. 2)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Comprehensive analysis of blood tryptophan metabolites and fatty acids in patients with lung cancer treated with immune checkpoint inhibitors
Acronym Tryptophan metabolites and fatty acids in ICI
Scientific Title Comprehensive analysis of blood tryptophan metabolites and fatty acids in patients with lung cancer treated with immune checkpoint inhibitors
Scientific Title:Acronym Tryptophan metabolites and fatty acids in ICI
Region
Japan

Condition
Condition lung cancer
Classification by specialty
Pneumology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To evaluate the utility of tryptophan metabolites and fatty acids for predicting efficacy of immune checkpoint inhibitors
Basic objectives2 Others
Basic objectives -Others Biomarker
Trial characteristics_1 Exploratory
Trial characteristics_2 Explanatory
Developmental phase Not applicable

Assessment
Primary outcomes Levels of blood tryptophan metabolites and fatty acids
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria Pathologically diagnosed non-small cell lung cancer patients who received immune checkpoint inhibitors
Key exclusion criteria Insufficient blood samples.
Target sample size 200

Research contact person
Name of lead principal investigator
1st name Takafumi
Middle name
Last name Suda
Organization Hamamatsu University School of Medicine
Division name Second division, Department of Internal Medicine
Zip code 431-3192
Address Handayama 1-20-1, Hamamatsu
TEL 053-435-2111
Email suda@hama-med.ac.jp

Public contact
Name of contact person
1st name Masato
Middle name
Last name Karayama
Organization Hamamatsu University School of Medicine
Division name Department of Chemotherapy
Zip code 431-3192
Address Handayama 1-20-1, Hamamatsu
TEL 053-435-2111
Homepage URL
Email karayama@hama-med.ac.jp

Sponsor
Institute Second division, Department of Internal Medicine, Hamamatsu University School of Medicine
Institute
Department

Funding Source
Organization Japan Science and Technology Agency
Organization
Division
Category of Funding Organization Japanese Governmental office
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Institutional Review Board of Hamamatsu University School of Medicine
Address Handayama 1-20-1, Hamamatsu
Tel 053-435-2111
Email kenkyou.k@hama-med.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2020 Year 01 Month 20 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2019 Year 06 Month 07 Day
Date of IRB
2019 Year 06 Month 07 Day
Anticipated trial start date
2019 Year 06 Month 07 Day
Last follow-up date
2021 Year 05 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information Not applicable

Management information
Registered date
2020 Year 01 Month 17 Day
Last modified on
2022 Year 07 Month 20 Day


Link to view the page
URL(English) https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044692